Marc Poirot

List of Publications by Year in descending order

111 papers	14,037 citations	101543 36 h-index	38395 95 g-index
115 all docs	115 docs citations	115 times ranked	26864 citing authors

#	Article	IF	Citations
1	Pharmacologic and genetic inhibition of cholesterol esterification enzymes reduces tumour burden: A systematic review and meta-analysis of preclinical models. Biochemical Pharmacology, 2022, 196, 114731.	4.4	5
2	Sterol metabolism and cancer. Biochemical Pharmacology, 2022, 196, 114843.	4.4	3
3	Oxysterols are potential physiological regulators of ageing. Ageing Research Reviews, 2022, 77, 101615.	10.9	21
4	Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosomeâ€enriched vesicles. Journal of Extracellular Vesicles, 2022, 11, e12211.	12.2	8
5	In vitro and In vivo oxidation and cleavage products of tocols: From chemical tuners to â€œVitaminEomeâ€•therapeutics. A narrative review. Food Bioscience, 2022, 49, 101839.	4.4	3
6	The 5,6â€epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets. British Journal of Pharmacology, 2021, 178, 3248-3260.	5.4	27
7	European network for oxysterol research (ENOR): 10 th anniversary. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105996.	2.5	4
8	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (edition	9.1	1,430
9	Vitamin E: an overview. , 2020, , 51-66.		4
10	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. Cancers, 2020, 12, 2933.	3.7	7
11	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
12	A fast UPLCâ€“HILIC method for an accurate quantii¬cation of dendrogenin A in human tissues. Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105447.	2.5	7
13	Oxysterols: An expanding family of structurally diversified bioactive steroids. Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105443.	2.5	9
14	The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 192, 105390.	2.5	22
15	Natural and semisynthetic oxyprenylated aromatic compounds as stimulators or inhibitors of melanogenesis. Bioorganic Chemistry, 2019, 87, 181-190.	4.1	9
16	Flavonoids differentially modulate liver X receptors activityâ€”Structure-function relationship analysis. Journal of Steroid Biochemistry and Molecular Biology, 2019, 190, 173-182.	2.5	22
17	HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris. Molecules, 2019, 24, 501.	3.8	14
18	Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3Î²,5Î±-diol (OCDO), a tumor promoter and cholesterol metabolite. Biochimie, 2018, 153, 139-149.	2.6	21

#	Article	IF	Citations
19	The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers. Biochemical Pharmacology, 2018, 153, 75-81.	4.4	48
20	Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment. Autophagy, 2018, 14, 555-557.	9.1	25
21	Extracellular vesicles: lipids as key components of their biogenesis and functions. Journal of Lipid Research, 2018, 59, 1316-1324.	4.2	208
22	Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation. Biomedicines, 2018, 6, 21.	3.2	9
23	The Effects of Cholesterol-Derived Oncometabolites on Nuclear Receptor Function in Cancer. Cancer Research, 2018, 78, 4803-4808.	0.9	45
24	Abstract 5238: Characterization of the enzyme generating the cholesterol metabolite and tumor suppressor dendrogenin A in the breast and its deregulations in breast cancer. , 2018, , .		0
25	Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. Journal of Steroid Biochemistry and Molecular Biology, 2017, 169, 210-218.	2.5	48
26	Improvement of 5,6Î±-epoxycholesterol, 5,6Î²-epoxycholesterol, cholestane-3Î²,5Î±,6Î²-triol and 6-oxo-cholestan-3Î²,5Î±-diol recovery for quantification by GC/MS. Chemistry and Physics of Lipids, 2017, 207, 92-98.	3.2	7
27	Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9346-E9355.	7.1	96
28	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
29	Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death. Biochemical Pharmacology, 2017, 144, 18-28.	4.4	43
30	Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry. Chemistry and Physics of Lipids, 2017, 207, 81-86.	3.2	8
31	When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite1. Biochemical Society Transactions, 2016, 44, 631-637.	3.4	17
32	From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite. Biochimie, 2016, 130, 109-114.	2.6	21
33	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
34	Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig. Frontiers in Aging Neuroscience, 2015, 7, 145.	3.4	11
35	Cholesterol metabolites exported from human brain. Steroids, 2015, 99, 189-193.	1.8	75
36	Human Monocyte Recognition of Adenosine-Based Cyclic Dinucleotides Unveils the A2a G_{Î±s} Protein-Coupled Receptor Tonic Inhibition of Mitochondrially Induced Cell Death. Molecular and Cellular Biology, 2015, 35, 479-495.	2.3	18

#	Article	IF	Citations
37	Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds. Frontiers in Oncology, 2015, 5, 287.	2.8	28
38	Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties. Current Medicinal Chemistry, 2015, 22, 3533-3549.	2.4	24
39	Abstract P3-05-12: Circulating oxysterol metabolites as potential new surrogate markers for hormonotherapy in patients with hormone receptor-positive breast cancer? A pilot study. , 2015, , .		0
40	Abstract 1165: Identification of a cholesterol onco-metabolite, promoter of tumor in breast cancers, and of the enzyme involved in its biosynthesis. Cancer Research, 2015, 75, 1165-1165.	0.9	1
41	Cholesterol and Cancer, in the Balance. Science, 2014, 343, 1445-1446.	12.6	182
42	Emerging concepts on the role of exosomes in lipid metabolic diseases. Biochimie, 2014, 96, 67-74.	2.6	62
43	One step synthesis of 6-oxo-cholestan-3Î²,5Î±-diol. Biochemical and Biophysical Research Communications, 2014, 446, 782-785.	2.1	11
44	Exosomes as new vesicular lipid transporters involved in cellâ€“cell communication and various pathophysiologies. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 108-120.	2.4	649
45	The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells. Biochemical and Biophysical Research Communications, 2014, 446, 681-686.	2.1	21
46	Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia. Blood, 2014, 124, 3767-3767.	1.4	0
47	5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells. Biochemical Pharmacology, 2013, 86, 175-189.	4.4	56
48	Cholesterol-5,6-epoxides: Chemistry, biochemistry, metabolic fate and cancer. Biochimie, 2013, 95, 622-631.	2.6	69
49	Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. Biochimie, 2013, 95, 1677-1688.	2.6	25
50	Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A. Biochimie, 2013, 95, 482-488.	2.6	1
51	Oxysterols and related sterols: Implications in pharmacology and pathophysiology. Biochemical Pharmacology, 2013, 86, 1-2.	4.4	9
52	Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Medical Physics, 2013, 40, 052501.	3.0	26
53	Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nature Communications, 2013, 4, 1840.	12.8	101
54	Generation of whole-body scintigraphic images with new GATE output capacities. , 2013, , .		1

#	Article	IF	Citations
55	Abstract 1662: Dendrogenin A is a newly identified mammalian steroidal alkaloid that induced autophagic cell death in melanoma cells through an LXRbeta-, Nur77- and Nor1-dependent way.. , 2013, , .		1
56	Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget, 2013, 4, 911-922.	1.8	27
57	Abstract 1884: 6-oxo-cholestan-3Î²,5Î±-diol (OCDO) is a metabolite produced in tumors by cholesterol epoxide hydrolase activity and a tumor promoter: OCDO inhibition contributes to the anti-tumor activity of tamoxifen and dendrogenin A.. , 2013, , .		0
58	MAPK14/p38Î± confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy, 2012, 8, 1098-1112.	9.1	79
59	Cholesterol metabolism and cancer: the good, the bad and the ugly. Current Opinion in Pharmacology, 2012, 12, 673-676.	3.5	67
60	Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles. Journal of Lipid Research, 2012, 53, 718-725.	4.2	36
61	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
62	Cholesterol epoxide hydrolase and cancer. Current Opinion in Pharmacology, 2012, 12, 696-703.	3.5	71
63	Cholesterol metabolism and resistance to tamoxifen. Current Opinion in Pharmacology, 2012, 12, 683-689.	3.5	49
64	Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor. Biochemical Pharmacology, 2012, 83, 627-632.	4.4	15
65	Abstract 956: The liver-X-receptor-Î± is involved in the induction by Tamoxifen of breast cancer cell differentiation and death. , 2012, , .		2
66	Four decades of discovery in breast cancer research and treatment an interview with V. Craig Jordan. International Journal of Developmental Biology, 2011, 55, 703-712.	0.6	15
67	Exosomes as intercellular signalosomes and pharmacological effectors. Biochemical Pharmacology, 2011, 81, 1171-1182.	4.4	471
68	Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chemistry and Physics of Lipids, 2011, 164, 432-437.	3.2	51
69	Abstract 938: Discovery of Dendrogenin A as the first endogenous alkylaminooxysterol present in mammals with potent cell differentiation and anticancer activity. , 2011, , .		2
70	Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to in vivo evaluation. Bioorganic and Medicinal Chemistry, 2010, 18, 5400-5412.	3.0	12
71	Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting. European Journal of Medicinal Chemistry, 2010, 45, 423-429.	5.5	8
72	R167 - Oral, Club Mex-H Quantification du volume tumoral rÃ©siduel des cancers du rectum post-radiochimiothÃ©rapie par histomorphomÃ©trie quantitative. Bulletin Du Cancer, 2010, 97, S82.	1.6	0

#	Article	IF	Citations
73	R42 â€“ Oral Un Â« bon et mauvais cholestÃ©rol Â» pour la thÃ©rapie et dans la pathophysiologie des cancers : les cholestÃ©rols Ã©poxydes et leurs dÃ©rivÃ©s sous les feux de la rampe. Bulletin Du Cancer, 2010, 97, S32.	1.6	0
74	R92: IntÃ©rÃªt de la modÃ©lisation molÃ©culaire dans le dÃ©veloppement de nouveaux radiopharmaceutiques en oncologie nuclÃ©aire. Bulletin Du Cancer, 2010, 97, S52.	1.6	0
75	R44: MÃ©diateurs lipidiques et cancer : les exosomes comme Â« signalosomes Â» intercellulaires transporteurs de prostaglandines. Bulletin Du Cancer, 2010, 97, S32-S33.	1.6	0
76	Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. Journal of Lipid Research, 2010, 51, 2105-2120.	4.2	528
77	Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13520-13525.	7.1	109
78	Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors. Molecular Pharmacology, 2010, 78, 827-836.	2.3	50
79	Correction for de Medina et al., Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14937-14937.	7.1	1
80	Ciblage peptidique en oncologie nuclÃ©aireÂ: intÃ©rÃªt de la modÃ©lisation molÃ©culaire. Medecine Nucleaire, 2010, 34, 289-294.	0.2	1
81	Abstract 2918: Molecular identification of the cholesterol-5,6-epoxide hydrolase: A new target for selective estrogen receptor modulators and unsaturated fatty acids. , 2010, , .		0
82	Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. Journal of Lipid Research, 2009, 50, 2203-2211.	4.2	64
83	Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy, 2009, 5, 1066-1067.	9.1	86
84	Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death and Differentiation, 2009, 16, 1372-1384.	11.2	72
85	Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2009, 52, 7765-7777.	6.4	55
86	Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Molecular Cancer Therapeutics, 2008, 7, 3707-3718.	4.1	56
87	Structure-based identification of ER and ACAT as molecular targets involved in the chemopreventive activity of the citrus auraptene. Planta Medica, 2008, 74, .	1.3	0
88	Preclinical evaluation of new radioligand of cholecystokinin/gastrin receptors in endocrine tumors xenograft nude mice. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2007, 571, 160-164.	1.6	0
89	Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation. Molecular Pharmacology, 2006, 70, 1935-1945.	2.3	8
90	The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 139-149.	2.5	20

#	Article	IF	Citations
91	Synthesis and Biological Properties of New Stilbene Derivatives of Resveratrol as New Selective Aryl Hydrocarbon Modulators. Journal of Medicinal Chemistry, 2005, 48, 287-291.	6.4	55
92	Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Research, 2005, 7, R1159-67.	5.0	29
93	Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 491-508.	7.0	67
94	Molecular Characterization of the Microsomal Tamoxifen Binding Site. Journal of Biological Chemistry, 2004, 279, 34048-34061.	3.4	84
95	Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1165-1173.	2.5	71
96	Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells. Biochemical Pharmacology, 2003, 65, 629-636.	4.4	5
97	High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene, 2003, 22, 6081-6089.	5.9	28
98	Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies. Molecular Pharmacology, 2003, 63, 973-982.	2.3	25
99	Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells. Endocrinology, 2003, 144, 989-998.	2.8	18
100	Identification of Two Tamoxifen Target Proteins by Photolabeling with 4-(2-Morpholinoethoxy)benzophenone. Bioconjugate Chemistry, 2002, 13, 766-772.	3.6	34
101	Synthesis, binding and structureâ€“affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorganic and Medicinal Chemistry, 2000, 8, 2007-2016.	3.0	27
102	Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. Biochemical Pharmacology, 1999, 57, 657-661.	4.4	19
103	Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor. Biochemical Pharmacology, 1999, 58, 1927-1939.	4.4	25
104	Different populations of progesterone receptorâ€“steroid complexes in binding to specific DNA sequences: effects of salts on kinetics and specificity. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 251-266.	2.5	5
105	Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site. Biochemical Journal, 1998, 334, 107-112.	3.7	28
106	Characterization of the Membranous Antiestrogen Binding Protein: II Purification to homogeneity. Journal of Receptors and Signal Transduction, 1994, 14, 37-46.	1.2	7
107	Characterization of the Membranous Antiestrogen Binding Protein: I Partial purification of the protein in its active state. Journal of Receptors and Signal Transduction, 1994, 14, 23-35.	1.2	8
108	Characterization of a benzyl-phenoxy-ethanamine binding protein in Trypanosoma equiperdum and the possible relation between binding affinity and trypanocidal activity. Molecular and Biochemical Parasitology, 1993, 58, 311-316.	1.1	0

#	Article	IF	Citations
109	Cytosolic Type II Estrogen Binding Site in Rat Uterus: Specific Photolabeling with Estrone. Journal of Receptors and Signal Transduction, 1992, 12, 217-231.	1.2	2
110	The anti-proliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not. Biochemical Pharmacology, 1990, 40, 425-429.	4.4	12
111	Further evidence for a biological role of anti-estrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives. Chemico-Biological Interactions, 1988, 66, 101-109.	4.0	29